Why the hip makes accurate injection harder than the knee

The hip sits deep. Reaching the anterior joint space requires a needle to travel through four to eight centimetres of overlying soft tissue — roughly three to four times the distance a clinician must cover for a straightforward knee injection. That depth alone raises the technical bar considerably, but anatomy adds a second complication that matters even more.

Running alongside the front of the hip capsule is a cluster of structures whose exact geometry varies from person to person. The femoral artery sits approximately 1.9 cm medial to the capsule; the femoral vein approximately 1.7 cm medial; the femoral nerve approximately 2.3 cm lateral. More unpredictably still, the lateral circumflex femoral artery (LCFA) courses directly over the anterior capsule — but at a position that differs between patients and cannot be inferred from the skin surface. No landmark — bony or palpable — reliably tells a clinician where that vessel is on a given day for a given patient.

The practical consequence is significant. With a shallow joint such as the knee, a needle placed a centimetre off-target may simply miss the joint space, which is inconvenient but manageable. With the hip, the same error carries the needle into territory shared by major vessels and nerves. A miss here is not a minor inaccuracy; it is a meaningful safety event.

That is why image guidance for hip injection is a clinical standard rather than an optional upgrade.

How often unguided hip injections miss the target

Figures from the surgical and injection literature put a concrete number on what that anatomical complexity costs in practice. A 2016 systematic review by Hoeber and colleagues — drawing on 120 citations and widely referenced across the musculoskeletal field — found that landmark-guided hip injections achieved accurate intra-articular placement in just 72% of cases (95% CI 56–85%). Image-guided techniques, by contrast, achieved 100% accurate placement (95% CI 98–100%), a difference that reached statistical significance at p<0.0001.

The roughly 28–30% failure rate is a reproducible figure across the orthobiologics literature, not a result confined to a single paper or study population.

For a corticosteroid or hyaluronic acid injection, missing the target is a setback: the patient receives a dose that largely bypasses the joint, symptom relief is curtailed, and a repeat appointment may be needed. Disappointing, but recoverable. For an acellular scaffold that gels in place within minutes of delivery, the implications of an off-target placement are of a different order entirely.

What real-time ultrasound does during a ChondroFiller hip injection

Placed against the hip before the needle is even introduced, an ultrasound probe produces a live cross-section of the joint on screen. That continuous image is what separates ultrasound guidance from simply checking position at the start and end of a procedure — the clinician is watching throughout, performing three simultaneous functions.

The first is tracking. As the needle advances through soft tissue, its tip appears as a bright echogenic point moving across the screen. The clinician sees the path, not just the destination — and if the trajectory drifts toward adjacent vessels or the variably positioned lateral circumflex femoral artery (whose course was described in the preceding section), the image shows it before any harm is done, not after.

The second function is confirmation of joint-space entry. Arrival at the intra-articular space is verified on screen before any ChondroFiller is released. This replaces the assumption-based 'loss of resistance' cue used in landmark technique with a visible, repeatable endpoint.

The third — and for ChondroFiller specifically the most consequential — is observation of scaffold distribution. As the collagen material is delivered, the clinician watches it spread across the articular surface in real time and can pause or adjust if the fill pattern looks uneven. Given that the scaffold sets within minutes of contact and cannot be moved once gelled, this brief observation window is the only point at which fill quality can be actively managed before delivery is completed.

Unlike fluoroscopy, ultrasound achieves all three functions without ionising radiation and with simultaneous soft-tissue and vascular detail.

Operator approach within guided injection still matters. A 2025 retrospective series of 276 hips using a lateral short-axis technique reported 99.3% adequate intra-articular fill and zero vascular complications; the authors specifically noted that the conventional anterior long-axis approach carries a risk of injury to the anteriorly located rotator artery. Image guidance is necessary — but selecting the right approach to the joint is part of the same clinical decision.

Why ChondroFiller's gelling behaviour makes placement precision non-negotiable

The distinction between ChondroFiller and a fluid injection such as hyaluronic acid or PRP begins at the molecular level. ChondroFiller works through acellular matrix-induced chondrogenesis — in practice, the scaffold acts as a framework that recruits the patient's own repair cells, drawing progenitor cells from the surrounding synovium and subchondral bone into the collagen matrix. It does not deliver exogenous cells; it supports the body's own repair process by creating the structural conditions for that repair to occur.

That mechanism depends entirely on the scaffold being positioned at the defect site. Ex vivo osteochondral work confirmed a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14 — cells migrating into the collagen framework precisely where it was placed. Scaffold deposited into pericapsular soft tissue rather than the articular lesion would meet a different biological environment, one not suited to chondrogenic differentiation.

This is why the material's gelling behaviour carries clinical weight that goes beyond logistics. The collagen polymerises in situ within minutes; once set, it cannot be aspirated, repositioned, or retrieved. Placement confirmed on-screen before delivery is the only window that exists. A misjudged deposit does not just reduce efficacy — it represents an irreversible outcome and a wasted CE-marked Class III device.

A 2024 biomechanical study adds a further dimension: ChondroFiller did not protect opposing cartilage under immediate full cyclic loading (33 N) due to initial mechanical instability after placement. Post-injection loading restriction is therefore part of the same clinical logic — the scaffold needs time to stabilise before the joint returns to normal function.

What the clinical evidence shows — and where gaps remain

The strongest published anchor for ChondroFiller's efficacy in the hip comes from a prospective cohort of 26 patients (Journal of Hip Preservation Surgery, 2021) in which 17 of the 21 patients available at final review achieved good or excellent outcomes at three to five years — an 81% rate for isolated acetabular lesions exceeding 2 cm² treated alongside correction of femoroacetabular impingement. The cohort applied strict entry criteria: Tönnis Grade 0–1 joint status was required, and patients with Tönnis Grade 2–3 pre-existing osteoarthritis did not achieve good results. That finding is relevant beyond the surgical setting — advanced joint degeneration appears to limit what the scaffold can achieve regardless of delivery route.

Biological plausibility for the injection pathway is supported by the ex vivo cell-recruitment data noted earlier, which demonstrated active migration into the scaffold within two weeks of contact. The 2025 retrospective series of 276 hips adds procedural safety evidence at scale: 99.3% adequate intra-articular fill and zero vascular complications. That study measured injection accuracy and vascular safety, however — it did not report long-term symptomatic outcomes.

Figures of 70–85% meaningful symptom relief at three to five years appear in injection-pathway publications from specialist centres, but these have not yet been evaluated in a peer-reviewed, hip injection-specific randomised controlled trial. That absence is the most significant gap in the current evidence base. Wrist arthroscopy data also suggest that overfilling a defect — as opposed to flush application — can produce fibrous tissue rather than cartilage-like repair, a precision risk that has not been studied specifically in hip injection contexts.

For patients weighing this option, the evidence picture combines credible biological mechanism, encouraging early procedural safety data, moderate-length surgical-cohort outcomes, and an acknowledged absence of randomised trial evidence for the injection route. That profile puts ChondroFiller alongside many other regenerative therapies at this stage of their clinical development — promising enough to merit serious consideration for the right presentation, but not yet supported by the highest level of evidence.

Who is suitable and how MSK Doctors delivers this pathway

Candidacy rests on three overlapping assessments. The cartilage lesion itself is graded on the ICRS scale (III–IV indicating full or near-full thickness loss); the overall arthritic burden of the joint is captured by the Tönnis grade (0–1 meaning minimal or no established osteoarthritis); and where wear is more diffuse, Kellgren-Lawrence grading describes the extent of joint-space change on plain radiograph. These are distinct measures of different aspects of joint health, but the clinical logic they share is consistent: ChondroFiller performs best where meaningful cartilage remains surrounding the defect and where the joint has not undergone advanced collapse. Published data from a three-to-five year surgical cohort make clear that Tönnis Grade 2–3 disease predicts poor results regardless of defect size.

For patients with more diffuse Kellgren-Lawrence Grade III or IV wear rather than a focal lesion, the scaffold may still have a role — acting as a top-down collagen support layer across degenerated surfaces rather than rebuilding a discrete focal defect from below. The evidence base for this indication is less mature, and realistic expectations should reflect that.

The appointment itself is outpatient: patients arrive, undergo imaging assessment and ultrasound-guided injection under local anaesthesia, and are discharged the same day. There is no theatre admission and no general anaesthetic. Post-injection, a period of reduced loading is standard advice while the scaffold stabilises — consistent with the biomechanical data discussed earlier.

Determining whether this profile fits an individual presentation requires a consultant review, including imaging. MSK Doctors sees patients at its Sleaford and Grantham clinics without the need for a GP referral.

1. [1] Arthroscopic utilisation of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12–60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759